Not Yet RecruitingPhase 1

Dose Escalation Study of Vinpocetine in Healthy Volunteers

20 participantsStarted 2025-06-01

Plain-language summary

The objective of this study is to determine whether vinpocetine is safe when taken at higher doses.

Age range18 Years – 40 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✕. Major medical disease (e.g., epilepsy, diabetes, heart disease, active cancer, depression).
✕. Those who score \>18 overall on the BDI-II or \>0 for item #9 (suicidal thoughts) at screening.
✕. Use of centrally active medications.
✕. History of allergy to vinpocetine.
✕. IQ\<80.
✕. BMI≥30.
✕. Pregnancy or lactation.

Adverse Events

Timeframe: Approximately weekly treatments across ~4-6 visits per participant.

NCT IDNCT06635746

SponsorStanford University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-06-01

Jordan Seliger